Recent non-hydroxamate matrix metalloproteinase inhibitors

摘要: Matrix metalloproteinases (MMPs) are a family of zinc-dependent endo-peptidases that have the capacity to degrade all elements extracellular matrix (ECM) and required for homeostatic maintenance ECM. Interest in MMPs arose from accumulating evidence implying over-activity plays role mediating or accompanying diverse array pathologies. Because this, there has been an ongoing, alas unsuccessful, effort nearly two decades develop clinically applicable MMP inhibitors (MMPIs) as drugs. The largest inhibitor candidates failed clinical trials is hydroxamic acids. This review i) attempts rationalise failure hydroxamates MMPIs, ii) critically reviews publications patents last few years, which report new non-hydroxamate based iii) summarises factors considered important success developing useful MMPIs.